- Pressemitteilung BoxID 44111
4SC to present at BioEquity Europe 2008
The presentation will be given by Dr Ulrich Dauer, Chief Executive Officer of 4SC AG on Thursday, 29 May 2008 at 3.00 p.m. local time. Dr Dauer will provide an overview of the company and update the audience on recent developments, umong them the progress of individual projects in the therapeutic pipeline.
Über 4SC AG
4SC AG (ISIN DE0005753818) has been listed in the Prime Standard of Frankfurt Stock Exchange since 15 December 2005. Founded in 1997 and now with a staff of 77 employees, the company develops novel drug candidates against inflammatory diseases and cancer. 4SC AG utilises its patent protected platform, to create a sustainable project pipeline of drug candidates, which are to be developed up to clinical efficacy in early clinical phases ('proof of concept') and subsequently partnered with the pharmaceutical industry in return for advance and milestone payments as well as royalties. There are currently eight projects in the development pipeline and a rich pool of further discovery projects. Clinical phase IIa for he first project for the treatment of rheumatoid arthritis has already successfully been completed. An additional project for the treatment of various cancers is currently completing a clinical phase I trial. Further projects are in advanced pre-clinical stages.
Further information is to be found at www.4sc.com.